MENU
+Compare
PPH
ETF ticker: NASDAQ
AS OF
Jan 17, 04:59 PM (EDT)
Price
$85.33
Change
-$1.15 (-1.33%)
Net Assets
565.53M

PPH stock forecast, quote, news & analysis

Category: @Health
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for PPH with price predictions
Jan 08, 2025

PPH in +0.64% Uptrend, advancing for three consecutive days on January 08, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PPH advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where PPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on January 06, 2025. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PPH as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PPH entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), McKesson Corp (NYSE:MCK), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 135.02B. The market cap for tickers in the group ranges from 2.48B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PDCO at 2.48B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was -1%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was -6%. ELAN experienced the highest price growth at 5%, while LLY experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was 16%. For the same stocks of the ETF, the average monthly volume growth was 4% and the average quarterly volume growth was 74%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 34
P/E Growth Rating: 58
Price Growth Rating: 58
SMR Rating: 59
Profit Risk Rating: 62
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com